Chandra K. Singh, PhD
Position title: Scientist II
Ahmad Laboratory Page
All Inquiries: Research and Administration
BS (Chemistry, Botany, & Zoology) 1998, VBS Purvanchal University, India
MS (Bioetechnology) 2002, University of Jammu, India
PhD (Biochemistry) 2008, University of Lucknow, India
2003-2008: Research Fellow, Food and Toxicology Division, Indian Institute of Toxicology Research (IITR), Lucknow, India
2008-2011: Post-doctoral Research Fellow, Dept. of Pathology, Microbiology, & Immunology, University of South Carolina, USA
My research interests lie in the field of biomedical research specifically focuses on (a) chemoprevention and experimental therapeutics, and (b) identification of molecular targets for intervention. My long-term research goal is to define the critical molecular and biochemical events as well as fundamental cancer driver pathways in the process of cancer development and progression that will help us to identify the targets for disease management.
Using natural resources and cutting-edge scientific knowledge, I want to identify and develop new molecules, approaches, and strategies that can ultimately be translated from the bench to the bedside for the prevention and/or treatment of cancer, specifically for skin and prostate cancer.
Singh CK, Denu RA, Nihal M, Shabbir M, Garvey DR, Huang W, Iczkowski KA, Ahmad N. PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence. The Prostate 2022, DOI: 10.1002/pros.24342
Kabay G, Yin Y, Singh CK, Ahmad N, Gunasekaran S, Mutlu M. Disposable electrochemical immunosensor for prostate cancer detection. Sensors and Actuators: B. Chemical 2022 https://doi.org/10.1016/j.snb.2022.131667
Thornton J, Chhabra G, Singh CK, Guzmán-Pérez G, Shirley CA, Ahmad N. Mechanisms of immunotherapy resistance in cutaneous melanoma: recognizing a shapeshifter. Front Oncol. 2022, https://www.frontiersin.org/articles/10.3389/fonc.2022.880876/abstract
Su S, Chhabra G, Singh CK, Ndiaye MA, Ahmad N. PLK1 inhibition-based combination therapies for cancer management. Transl Oncol. 2022, 16:101332. PMID: 34973570
Chhabra G, Singh CK, Guzmán-Pérez G, Ndiaye MA, Iczkowski KA, Ahmad N. Antimelanoma Effects of Concomitant Inhibition of SIRT1 and SIRT3 in BrafV600E/PtenNULL Mice. J Invest Dermatol. 2021, S0022-202X(21)02223-5. PMID: 34597611
Singh CK, Chhabra G, Patel A, Chang H, Ahmad N. Dietary Phytochemicals in Zinc Homeostasis: A Strategy for Prostate Cancer Management. Nutrients 2021 30;13(6):1867. PMID: 34070833
Singh CK, George J, Chhabra G, Nihal M, Chang H, Ahmad N. Genetic Manipulation of Sirtuin 3 Causes Alterations of Key Metabolic Regulators in Melanoma. Front Oncol. 2021, 16;11:676077. PMID: 33937086
Chhabra G, Singh CK, Amiri D, Akula N, Ahmad N. Recent advancements on immunomodulatory mechanisms of resveratrol in tumor microenvironment. Molecules. 2021; 26(5): 1343. PMID: 33802331
Singh CK*, Panackal JE, Siddiqui S, Ahmad N, Nihal M. Combined inhibition of specific sirtuins as a potential strategy to inhibit melanoma growth. Front. Oncol. 2020, 10:591972. PMID: 33178616 (* Corresponding author).
Su S, Chhabra G, Ndiaye MA, Singh CK, Ye T, Huang W, Dewey CN, Setaluri V, Ahmad N. PLK1 and NOTCH positively correlate in melanoma and their combined inhibition results in synergistic modulations of key melanoma pathways. Mol Cancer Ther. 2021; 20(1):161-172. PMID: 33177155